Study of SYS6055 for patients with B-cell cancer that returned or didn't respond to treatment
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called SYS6055 for people with B-cell cancers (leukemia or lymphoma) that have not improved or have come back after standard treatments. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of blood cancer called B-cell malignancy that is CD19-positive (a specific marker on the cancer cells)
- Your cancer has not responded to standard treatments or has come back after treatment
- You have at least one tumor that can be measured on a scan
- You are able to take care of yourself most of the day (ECOG score 0 or 1)
- You agree to use effective birth control during the study and for 1 year after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called SYS6055 for people with an aggressive form of B-cell lymphoma that has stopped responding to or returned after standard treatments. The goal is to see if this therapy can help shrink tumors and improve outcomes.
This study tests a new drug (SYS6005) that targets a protein called ROR1 on certain cancer cells. It is for people with advanced solid tumors or B-cell lymphomas that have stopped responding to other treatments.
This trial tests a new drug called SYS6040 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This Phase 1 study tests whether a new drug called SYS6051 is safe and effective for people with advanced solid tumors (cancer that has spread). Researchers will evaluate how well your body tolerates the drug and monitor for side effects.
This trial tests a new drug, SYS6043, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the tumor.
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Hear when a new Relapsed/Refractory B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.